Veradigm | MDRX - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Alcidion AUD 2.2M 1.76M 2025-12
Ambu A/S DKK 221M 48M 2026-06
Amplifon EUR 79.86M 25.61M 2026-06
Cardinal Health USD 814M 47M 2026-06
Centene USD -43.18B 45.04B 2026-06
Charles River Laboratories USD 119.89M 9K 2026-06
Cigna USD 2.76B 204M 2026-03
Coloplast 1.85B 102M 2025-12
Convatec Group USD 175.7M 101.1M 2024-12
CVS Health USD 6.73B 2.05B 2026-06
Diasorin EUR 56M 8.57M 2026-03
Elevance Health USD 2.3B 8.11B 2026-06
General Electric Aerospace USD 2.32B 549M 2026-03
Gulf Medical Proj AED 25.67M 5.13M 2026-03
Humana USD 1.36B 394M 2026-06
IQVIA Holdings USD 2.6B 2.03B 2026-06
Laboratory Of America USD 456.7M 46.6M 2026-06
Maximus USD 161.43M 12.94M 2026-06
McKesson USD 1.42B 415M 2026-06
Med Life RON 43.91M 3.82M 2026-03
Molina Healthcare USD 157M 19M 2026-06
Omnicell USD 36.32M 19.28M 2026-06
Oriola-kd EUR 4.4M 1000K 2026-03
Owens Minor USD 814K 28.08M 2025-12
Quest Diagnostics USD 459M 60M 2026-06
Rede D'or Sao Luiz BRL 3B 84.36M 2026-06
Siemens Healthineers EUR 947M 221M 2026-06
Sonova Holding CHF 296.8M 156.9M 2025-12
Supermax Corporation Bhd MYR -40.85M 22.71M 2026-03
UnitedHealth USD 7.99B 1.05B 2026-06
Veeva Systems USD 275.02M 1.91M 2026-06
Veradigm USD -45.47M 70.47M 2022-12
Xerox USD 30M 48M 2025-06